The second-generation inhibitors, afatinib and dacomitinib, were designed to irreversibly bind to the kinase domain of both EGFR and other ErbB family members but also failed to improve clinical outcomes as a single agent therapy in recurrent GBM patients [65,66,67]. The gene discussed is EGFR; the disease is glioblastoma.